

**NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Secukinumab.

[Updated 2018 Dec 3].

**Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



### Secukinumab

Revised: December 3, 2018.

CASRN: 1229022-83-6

# **Drug Levels and Effects**

## **Summary of Use during Lactation**

No information is available on the clinical use of secukinumab during breastfeeding. Because secukinumab is a large protein molecule with a molecular weight of 151,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, secukinumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

### **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

#### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

## **Alternate Drugs to Consider**

(Psoriasis) Adalimumab, Etanercept, Infliximab, Phototherapy, Tretinoin

# **Substance Identification**

#### **Substance Name**

Secukinumab

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

# **CAS Registry Number**

1229022-83-6

# **Drug Class**

Breast Feeding

Lactation

Antibodies, Monoclonal

Dermatologic Agents